The 27 references in paper A. Karabaeva Zh., A. Essaian M., I. Kayukov G., А. Карабаева Ж., А. Есаян М., И. Каюков Г. (2008) “КОНЦЕНТРАЦИЯ АЛЬДОСТЕРОНА, СОСТОЯНИЕ ГЕМОСТАЗА И ЭНДОТЕЛИАЛЬНОЙ ФУНКЦИИ У БОЛЬНЫХ НА ПРОГРАММНОМ ГЕМОДИАЛИЗЕ И ВЛИЯНИЕ НА НИХ ТЕРАПИИ СПИРОНОЛАКТОНОМ // CONCENTRATION OF ALDOSTERONE, STATE OF HEMOSTASIS ANВ ENDOTHELIAL FUNCTION IN PATIENTS ON PROGRAMMED HEMODIALYSIS AND EFFECTS OF EXPOSURE TO THERAPY WITH SPIRONOLACTONE” / spz:neicon:nefr:y:2008:i:2:p:56-60

1
Collins AJ, Schilling L, Ma JZ, Herzog CH. Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis
(check this in PDF content)
2
01; 38: S26-S29 2. Schillaci G, Reboldi G, Verdechia P High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. Arch Intern Med 2001; 161: 886-891
(check this in PDF content)
3
Garg AX, Clark FC, Haynes RB, House AA. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int 2002; 61: 1486-1494
(check this in PDF content)
4
Weyer C, Yudkin JS, Stehouwer CD et al. Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis 2002; 161: 233-242
(check this in PDF content)
5
Festa A, D’Agostino R Jr, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 2002; 51: 1131-1137
(check this in PDF content)
6
Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004; 291: 1978-1986
(check this in PDF content)
7
Rossi R, Cioni E, Nuzzo A et al. Endothelial-dependent vasodilation and incidence of type 2 diabetes in a population of healthy postmenopausal women. Diabetes Care 2005; 28: 702­ 707
(check this in PDF content)
8
Widlansky ME, Gokce N, Keaney JF Jr, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003; 42: 1149-1160
(check this in PDF content)
9
Epstein M. Aldosterone as a mediator of progressive renal dysfunction: evolving perspectives. Intern Med 2001 Jul; 40(7): 573-583
(check this in PDF content)
10
Epstein M. Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. Nephrol Dial Transpl 2003; 18(10): 1984-1992
(check this in PDF content)
11
Weber KT. Aldosterone in congestive hear failure. N Engl J Med 2001; 345: 1689-1697
(check this in PDF content)
12
Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension 2005; 46: 1227-1246
(check this in PDF content)
13
Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717
(check this in PDF content)
14
Gross E, Rothstein M, Dombek S, Juknis HI. Effect of Spironolactone on Blood Pressure and the Renin-AngiotensinAldosterone System in Oligo-Anuric Hemodialysis Patients. Am J Kidney Dis 2005; 46(1): 94-101
(check this in PDF content)
15
Saudan P, Mach F, Perneger Th et al. Safety of low-dose spironolactone administration in chronic haemodialysis patients. Nephrol Dial Transplant 2003; 18: 2359-2363
(check this in PDF content)
16
Arima S, Kohagura K, Xu HL et al. Nongenomic vascular action of aldosterone in glomerular microcirculation J Am Soc Nephrol 2003; 14 (9): 2253-2255
(check this in PDF content)
17
Norris K, Vaughn C. The role of rennin-angiotensin- aldosterone system in chronic kidney disease. Expert Rev Cardiovasc Ther 2003; 1 (1): 51-63
(check this in PDF content)
18
Nishiyama A, Yao L, Nagai Y Miyata K, Yoshizumi M, Kagami S et al. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 2004; 43: 841-848
(check this in PDF content)
19
Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63: 1791-1800
(check this in PDF content)
20
Peng H, Carretero OA, Raij L, Yang F, Kapke A, Rhaleb NE. Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats. Hypertension 2001; 37: 794-800
(check this in PDF content)
21
Nishiyama A, Abe Y. Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effects of aldosterone blockade. J Pharmacol Sci 2006; 1: 9-16
(check this in PDF content)
22
Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996; 98: 1063-1068
(check this in PDF content)
23
Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke- prone hypertensive rats. Hypertension 1998; 31: 451-458
(check this in PDF content)
24
Brown NJ, Kim K-S, Chen Y-Q et al. Synergistic Effect of Adrenal Steroids and Angiotensin II on Plasminogen Activator Inhibitor-1 Productions The Journal of Clinical Endocrinology & Metabolism 2000; 85(1): 336-344
(check this in PDF content)
25
Connell JMC, Davies E. The new biology of aldosterone. Journal of Endocrinology 2005; 186: 1-20
(check this in PDF content)
26
Cases A, Bragulat E, Serradell M et al. Endothelial dysfunction in chronic renal failure. Nephrologia 2003; 23(4): 42-51
(check this in PDF content)
27
Landray MJ, Wheeler DC et al. Inflammation, Endothelial dysfunction and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) Study. Am J Kidney Dis 2004; 43 (2): 244­ 253
(check this in PDF content)